新诊断乳腺癌患者术前MRI对侧乳腺筛查的长期结局
该回顾性研究纳入2008年1月至2010年12月连续新诊断乳腺癌患者1199例,比较术前MRI组与未MRI组,中位随访10年。倾向性评分2:1匹配后705例,MRI组对侧同时性病变检出率更高(5.7% vs 2.1%,P=0.047),总生存期更高(HR 2.51,95%CI 1.25-5.06,P=0.01);异时性病变率和病因特异性生存无差异。肿瘤>2cm及组织学III级患者MRI获益更明显。
要点
- 术前MRI筛查对侧乳腺可提高对侧同时性病变检出率(5.7% vs 2.1%,P=0.047)。
- MRI组总生存期高于未MRI组(HR 2.51,95%CI 1.25-5.06,P=0.01)。
- 肿瘤>2cm(HR 2.58)和组织学III级(HR 2.94)患者MRI获益更明显。
核心结论
- 新诊断乳腺癌后常规MRI筛查对侧乳腺改善了总生存期,原发肿瘤较大和组织学III级患者获益最明显。
研究设计与样本
- 回顾性研究,纳入2008年1月至2010年12月连续新诊断乳腺癌患者1846例中符合纳入标准1199例,中位随访10年(范围0-14年),倾向性评分2:1匹配后705例(MRI组470例,未MRI组235例),采用Kaplan-Meier法估计病因特异性生存和总生存,边缘Cox比例风险模型评估MRI与临床病理变量与总生存的关联。
诊断标准与关键数值
- MRI组对侧同时性病变27/470例(5.7%)vs 未MRI组5/235例(2.1%),P=0.047。
- 总生存:MRI组 vs 未MRI组 HR 2.51(95%CI 1.25-5.06),P=0.01。
- 异时性病变率:MRI组21/470例(4.5%)vs 未MRI组10/235例(4.3%),P>0.99。
- 病因特异性生存:HR 1.34(95%CI 0.56-3.21),P=0.51。
- 肿瘤>2cm亚组总生存HR 2.58(95%CI 1.11-5.99),P=0.03;组织学III级亚组HR 2.94(95%CI 1.18-7.32),P=0.02。
临床应用与阅片要点
- 术前MRI可检出对侧同时性病变(5.7% vs 2.1%),阅片时应关注对侧乳腺。
- MRI组总生存期更高(HR 2.51),但病因特异性生存无差异(HR 1.34,95%CI 0.56-3.21,P=0.51)。
- 原发肿瘤>2cm或组织学III级患者MRI获益更明显(HR分别为2.58和2.94)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Background The diagnostic value of screening the contralateral breast with MRI in patients with newly diagnosed breast cancer is poorly understood. Purpose To assess the impact of MRI for screening the contralateral breast on long-term outcomes in patients with newly diagnosed breast cancer and to determine whether subgroups with unfavorable prognoses would benefit from MRI in terms of survival. Materials and Methods Data on consecutive patients with newly diagnosed breast cancer seen from January 2008 to December 2010 were reviewed retrospectively. Patients with neoadjuvant chemotherapy, previous breast cancer, distant metastasis, absence of contralateral mammography at diagnosis, and no planned surgical treatment were excluded. Groups that did and did not undergo preoperative MRI were compared. Survival analysis was performed using the Kaplan-Meier method for propensity score-matched groups to estimate cause-specific survival (CSS) and overall survival (OS). A marginal Cox proportional hazards model was used to evaluate association of MRI and clinicopathologic variables with OS. Results Of 1846 patients, 1199 fulfilled the inclusion criteria. Median follow-up time was 10 years (range, 0-14 years). The 2:1 matched sample comprised 705 patients (470 in the MRI group and 235 in the no-MRI group); median ages at surgery were 59 years (range, 31-87 years) and 64 years (range, 37-92 years), respectively. MRI depicted contralateral synchronous disease more frequently (27 of 470 patients [5.7%] vs five of 235 patients [2.1%]; P = .047) and was associated with a higher OS (hazard ratio [HR], 2.51; 95% CI: 1.25, 5.06; P = .01). No differences were observed between groups in metachronous disease rate (MRI group: 21 of 470 patients [4.5%]; no-MRI group: 10 of 235 patients [4.3%]; P > .99) or CSS (HR, 1.34; 95% CI: 0.56, 3.21; P = .51). MRI benefit was greater in patients with larger tumor sizes (>2 cm) (HR, 2.58; 95% CI: 1.11, 5.99; P = .03) and histologic grade III tumors (HR, 2.94; 95% CI: 1.18, 7.32; P = .02). Conclusion Routine MRI screening of the contralateral breast after first diagnosis of breast cancer improved overall survival; the most pronounced benefit was found in patients with larger primary tumor size and primary tumors of histologic grade III. © RSNA, 2022 Online supplemental material is available for this article. See also the editorial by Taourel in this issue.
引用
- Freitas V, Li X, Amitai Y, et al. Contralateral Breast Screening with Preoperative MRI: Long-Term Outcomes for Newly Diagnosed Breast Cancer. Radiology. 2022. PMID: 35471109. doi:10.1148/radiol.212361
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。